Page 89 - GTM-4-2

Global Translational Medicine Angiotensinogen in liver steatosis

Ethics approval and consent to participate disease-Meta-analytic assessment of prevalence, incidence,
and outcomes. Hepatology. 2016;64:73-84.
All experiments were performed according to a protocol
approved by the Institutional Animal Care and Use doi: 10.1002/hep.28431
Committee at the University of Kentucky (Protocol 2. Cotter TG, Rinella M. Nonalcoholic fatty liver disease
#2015-2050) in accordance with the guidelines of the 2020: The state of the disease. Gastroenterology.
National Institutes of Health. 2020;158:1851-1864.
Consent for publication doi: 10.1053/j.gastro.2020.01.052
3. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev
Not applicable. Gastroenterol Hepatol. 2013;10:686-690.
Availability of data doi: 10.1038/nrgastro.2013.171
RNA sequencing data (raw FASTQ and aligned data) are 4. Teng ML, Tan DJH, Ng CH, Huang DQ. Hepatocellular
publicly available at the gene expression omnibus (GEO) carcinoma surveillance in non-alcoholic fatty liver disease-
who and how? Clin Mol Hepatol. 2023;29:404-407.
repository (GSE291082). The data that support the findings
of this study are also available from the corresponding doi: 10.3350/cmh.2023.0069
authors on reasonable request. 5. Gwaltney-Brant SM. In: Gupta RC, editor. Nutraceuticals in
Renal Diseases. Ch. 8. United States: Academic Press; 2016.
Further disclosure p. 101-108.
The findings which are presented in the current manuscript 6. Ma W, Wu W, Wen W, et al. Association of NAFLD with
in Figure 2A and Figure 3C were previously presented at cardiovascular disease and all-cause mortality: A large-scale
the following conferences: prospective cohort study based on UK Biobank. Ther Adv
Chronic Dis. 2022;13:20406223221122478.
1. 09/2022 Pettey, AC, Sawada, H, Ye, D, Wu, C, Daugherty,
A, Lu, HS. Hepatocyte-specific angiotensinogen doi: 10.1177/20406223221122478
deficiency prevents Western diet-induced fatty liver 7. Engin A. Non-alcoholic fatty liver disease. Adv Exp Med
in mice. Fredrickson Lipid Research Conference, Biol. 2017;960:443-467.
Durham, NC, USA. Poster presentation by Pettey AC. doi: 10.1007/978-3-319-48382-5_19
2. 10/2022 Pettey, AC, Sawada, H, Amioka, N, Ye, D,
Wu, C, Daugherty, A, Lu, HS. Hepatocyte-specific 8. Yki-Jarvinen H, Luukkonen PK, Hodson L, Moore JB.
deletion of angiotensinogen ameliorates Western Dietary carbohydrates and fats in nonalcoholic fatty liver
diet-induced hepatic steatosis with a suppression of disease. Nat Rev Gastroenterol Hepatol. 2021;18:770-786.
the transcriptome related to inflammation. Kentucky doi: 10.1038/s41575-021-00472-y
Chapter of the American Physiological Society 9. Stephenson K, Kennedy L, Hargrove L, et al. Updates on
Annual Meeting, University of Kentucky. Oral and dietary models of nonalcoholic fatty liver disease: Current
poster presentations by Pettey AC. studies and insights. Gene Expr. 2018;18:5-17.
3. 10/2022 Pettey, AC, Sawada, H, Amioka, N, Ye, D, doi: 10.3727/105221617X15093707969658
Wu, C, Daugherty, A, Lu, HS. Western diet-induced
hepatic steatosis is ameliorated by hepatocyte- 10. Matsusaka T, Niimura F, Shimizu A, et al. Liver
angiotensinogen is the primary source of renal angiotensin II.
specific angiotensinogen deletion with suppression J Am Soc Nephrol. 2012;23:1181-1189.
of complement component C4. Saha Cardiovascular
Research Day, Lexington, KY, USA. Poster presentation doi: 10.1681/ASN.2011121159
by Pettey AC. 11. Lu H, Wu C, Howatt DA, et al. Angiotensinogen exerts
4. 5/2023 Pettey AC, Sawada H, Ye D, Wu C, Daugherty effects independent of Angiotensin II. Arterioscler Thromb
A, Lu HS. Complement component C4 suppression Vasc Biol. 2016;36:256-265.
accompanies abatement of steatosis in hepatocyte- doi: 10.1161/ATVBAHA.115.306740
specific angiotensinogen deficient mice. Vascular 12. Kukida M, Cai L, Ye D, et al. Renal angiotensinogen is
Discovery. Boston, MA, USA. Poster presentation by predominantly liver derived in nonhuman primates.
Pettey AC. Arterioscler Thromb Vasc Biol. 2021;41:2851-2853.

References doi: 10.1161/atvbaha.121.316590
1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, 13. Daugherty A, Sawada H, Sheppard MB, Lu HS.
Wymer M. Global epidemiology of nonalcoholic fatty liver Angiotensinogen as a therapeutic target for cardiovascular

Volume 4 Issue 2 (2025) 81 doi: 10.36922/gtm.6027